{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T13:40:03Z","timestamp":1777556403041,"version":"3.51.4"},"reference-count":31,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Technology &amp; Therapeutics"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n                    <jats:title>Context:<\/jats:title>\n                    <jats:p>Limited evidence is available on the real-world effect of insulin degludec (IDeg) in type 1 diabetes (T1D), using continuous glucose monitoring (CGM)-derived metrics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To assess the real-world effect of switching to IDeg from other long-acting insulins on time in ranges (TIRs) measured by CGM, metabolic control, and insulin dose for people with T1D.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>This retrospective multicenter study encompassed five time points during a 12-month pre-switch of IDeg and a 12-month follow-up period. For each visit, clinical and CGM data were collected to evaluate temporal trends in glycemic outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants:<\/jats:title>\n                    <jats:p>Of 753 persons with T1D who were assessed for eligibility, 486 persons were included, mostly men (61.5%), 47.4 (16.9) years old and diabetes duration of 23.8 (14.2) years at IDeg-initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcome Measure:<\/jats:title>\n                    <jats:p>Primary outcome was the evolution of percent TIR (70\u2013180\u2009mg\/dL or 3.9\u201310.0\u2009mmol\/L, TIR) before versus after switch to IDeg.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      TIR over 24\u2009h increased at 12 months versus baseline (56.7% vs. 52.3%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u20090.001), mostly during daytime. Time &lt;54\u2009mg\/dL (&lt;3.0\u2009mmol\/L) over 24\u2009h decreased at 12 months versus baseline (2.02% vs. 2.86%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u20090.001), mostly during nighttime. Glycated hemoglobin (7.9% vs. 8.1%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u20090.001) and coefficient of variation (40.0% vs. 41.5%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u20090.001) improved at 12 months versus baseline. Mean daily basal, bolus and total insulin doses decreased at 12 months (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u20090.001 for all vs. baseline).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This retrospective real-world study reports that switching basal insulin significantly improved time spent in glucometric ranges and glycemic variability in the studied population of people with T1D.<\/jats:p>\n                    <jats:p>Clinical Trial Registration number: NCT05434559.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/dia.2023.0616","type":"journal-article","created":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T11:56:13Z","timestamp":1711022173000},"page":"587-595","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Continuous Glucose Monitoring-Derived Glucometrics in Adults with Type 1 Diabetes When Switching Basal Insulins"],"prefix":"10.1177","volume":"26","author":[{"given":"Robbe","family":"De Groote","sequence":"first","affiliation":[{"name":"Department of Endocrinology, University Hospitals Leuven\u2014KU Leuven, Leuven, Belgium."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eveline","family":"Lefever","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, University Hospitals Leuven\u2014KU Leuven, Leuven, Belgium."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2100-4927","authenticated-orcid":false,"given":"Sara","family":"Charleer","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, University Hospitals Leuven\u2014KU Leuven, Leuven, Belgium."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phebe","family":"Donn\u00e9","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology and Metabolism, University of Antwerp\u2014Antwerp University Hospital, Edegem, Belgium."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0679-3203","authenticated-orcid":false,"given":"Christophe De","family":"Block","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetology and Metabolism, University of Antwerp\u2014Antwerp University Hospital, Edegem, Belgium."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chantal","family":"Mathieu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, University Hospitals Leuven\u2014KU Leuven, Leuven, Belgium."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9111-4561","authenticated-orcid":false,"given":"Pieter","family":"Gillard","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, University Hospitals Leuven\u2014KU Leuven, Leuven, Belgium."},{"name":"Fonds Wetenschappelijk Onderzoek (FWO), Brussels, Belgium."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,8,8]]},"reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2017.39"},{"key":"e_1_3_7_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-012-0739-z"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01638.x"},{"key":"e_1_3_7_5_2","unstructured":"Novo Nordisk. Summary of Product Characteristics Tresiba\u00ae. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tresiba-epar-product-information_en.pdf [Last accessed: December27 2023]."},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01627.x"},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12938"},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-1033"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2017.10.001"},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60204-9"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-3249"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12298"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.7115"},{"key":"e_1_3_7_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14574"},{"key":"e_1_3_7_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15003"},{"key":"e_1_3_7_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14898"},{"key":"e_1_3_7_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13149"},{"key":"e_1_3_7_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/dme.13976"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-021-01063-5"},{"key":"e_1_3_7_20_2","doi-asserted-by":"publisher","DOI":"10.6084\/m9.figshare.10042994"},{"key":"e_1_3_7_21_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2019-01021"},{"key":"e_1_3_7_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-020-00982-z"},{"key":"e_1_3_7_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-021-01153-4"},{"key":"e_1_3_7_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00319-9"},{"key":"e_1_3_7_25_2","doi-asserted-by":"publisher","DOI":"10.1177\/19322968221085273"},{"key":"e_1_3_7_26_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S006"},{"key":"e_1_3_7_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/pedi.12817"},{"key":"e_1_3_7_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13559"},{"key":"e_1_3_7_29_2","unstructured":"CHMP. Guideline on Clinical Investigation of Medicinal Products in the Treatment or Prevention of Diabetes Mellitus. European Medicines Agency: United Kingdom; 2012. Available from: www.ema.europa.eu [Last accessed: July18 2023]."},{"key":"e_1_3_7_30_2","unstructured":"FDA. Guidance for Industry Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention. U.S. Department of Health and Human Services; 2008. Available from: https:\/\/www.fda.gov\/cder\/guidance\/index.htm [Last accessed: July18 2023]."},{"key":"e_1_3_7_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00245-X"},{"key":"e_1_3_7_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)17670-8"}],"container-title":["Diabetes Technology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/dia.2023.0616","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2023.0616","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/dia.2023.0616","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:14:40Z","timestamp":1777400080000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/dia.2023.0616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1089\/dia.2023.0616"],"URL":"https:\/\/doi.org\/10.1089\/dia.2023.0616","relation":{},"ISSN":["1520-9156","1557-8593"],"issn-type":[{"value":"1520-9156","type":"print"},{"value":"1557-8593","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8]]}}}